Secondary Plasma Cell Leukemia Life Expectancy

Plasma cell leukemia pcl is a plasma cell dyscrasia i e.

Secondary plasma cell leukemia life expectancy.

Plasma cell leukemia is a rare and typically very aggressive form of blood cancer. Secondary plasma cell leukemia represents an aggressive proliferative disorder associated with a poor prognosis and a shorter survival compared to mm itself. I was diagnosed with primary plasma cell leukemia in 2012. Given that actual treatment of spcl is unsatisfactory novel therapeutic approaches are needed in order to improve outcome and quality of life in these patients.

When patients develop plasma cell leukemia after their original multiple myeloma it is secondary plasma cell leukemia. Secondary plasma cell leukemia occurs in 1 to 4 patients out of 100 patients who are with myeloma and it is becoming more common as the life span of myeloma patients is increasing. Normal plasma cells in the bone marrow produce antibodies that fight infection. Plasma cell leukemia is more commonly seen in african americans than caucasians.

Men are at a slightly increased risk for developing plasma cell leukemia than women. Pcl manifests when the cancerous plasma cells are seen in the bloodstream not just in the bone marrow. I had never had myeloma before it was my original diagnosis. Plasma cell leukemia pcl is an aggressive form of multiple myeloma characterized by high levels of abnormal plasma cells circulating in the peripheral circulating blood.